Standard BioTools Inc. (LAB)
| Market Cap | 258.67M -47.1% |
| Revenue (ttm) | 84.60M -4.8% |
| Net Income | 84.91M |
| EPS | 0.22 |
| Shares Out | 392.58M |
| PE Ratio | 3.05 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 370,315 |
| Open | 0.6588 |
| Previous Close | 0.6578 |
| Day's Range | 0.6450 - 0.6717 |
| 52-Week Range | 0.6251 - 1.7200 |
| Beta | 1.35 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 3, 2026 |
About LAB
Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneo... [Read more]
Financial Performance
In 2025, Standard BioTools's revenue was $85.33 million, a decrease of -6.24% compared to the previous year's $91.01 million. Losses were -$74.90 million, -59.49% less than in 2024.
Financial StatementsNews
Standard BioTools to sell Microfluidics business to Archimed, terms undisclosed
Standard BioTools (LAB) announced it has entered into a definitive agreement to sell its Microfluidics business to Archimed. Michael Egholm, president and CEO of Standard BioTools, said, “Archimed bri...
Standard BioTools Announces Agreement to Sell Microfluidics Business to ARCHIMED
BOSTON, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced it has entered into a definitive agreement to sell its Micr...
Standard BioTools provides update on sale of mass cytometry business
Standard BioTools (LAB) announced updates in connection with the company’s merger with Treeline Biosciences. Standard BioTools terminated its previously announced agreement to sell its Mass Cytometry ...
Standard BioTools Provides Update on Sale of Mass Cytometry Business
Standard BioTools Enters into New Purchase Agreement with Element Biosystems, a Subsidiary of GMT Venture, After Determining GMT Venture's Unsolicited Acquisition Proposal as Superior Standard BioTool...
Standard BioTools Reports Second Quarter 2026 Financial Results
BOSTON, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended June 30, 2026.
Standard BioTools Earnings release: Q2 2026
Standard BioTools released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.
Standard BioTools Quarterly report: Q2 2026
Standard BioTools has published its Q2 2026 quarterly earnings report on August 5, 2026.
Standard BioTools to sell Mass Cytometry business to Multiplex Bio for $10M
Standard BioTools (LAB) announced the following updates in connection with the company’s previously announced merger with Treeline Biosciences. Agreement to sell its Mass Cytometry business to Multipl...
Standard BioTools Announces Sale of Mass Cytometry Business and Illumina's Buyout of Contingent Payments to Advance Merger with Treeline Biosciences
Sale of Mass Cytometry Business to Multiplex Bio Ensures Full Continuity of CyTOF and Hyperion Product Lines, Customer Relationships, Dedicated Team and Continued Investment in Next Generation Multipl...
Standard BioTools to Announce Second Quarter 2026 Financial Results on August 5, 2026
BOSTON, Mass., July 22, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will publish its second quarter 2026 financial results on Wednesday, August 5, 2026, after...
Standard BioTools files registration statement for Treeline Biosciences merger
Standard BioTools (LAB) announced the filing of a registration statement on Form S-4 with the SEC in connection with its previously announced definitive merger agreement with Treeline Biosciences. Upo...
Standard BioTools Announces Filing of Registration Statement in Connection with Treeline Biosciences Transaction
Highlights combined company's strong financial position with over $900 million expected at closing, Treeline's deep clinical-stage pipeline, planned 2027 data updates for TLN-121 and TLN-372, and expe...
Standard BioTools Transcript: AGM 2026
The meeting covered director elections, executive compensation, auditor ratification, and equity plan approvals, with all proposals passing. No questions were submitted during the Q&A, and forward-looking risks were highlighted.
LiveRamp Launches Agentic Partner Program to Fast-Track Agentic Deployments for Customers
SAN FRANCISCO--(BUSINESS WIRE)--LiveRamp (NYSE: RAMP), the leader in data collaboration, today announced LiveRamp Agent Builders (LAB), a new program to bring more partner-built agents into its networ...
Labrador Gold to Host Investor Webinar on the Mariposa Gold Project in Yukon's White Gold District
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Labrador Gold Corp. (TSX Venture: LAB) ("Labrador Gold" or the "Company") is pleased to announce that it will host a live investor webinar on Wednesday, June...
Labrador Gold Announces 2026 Exploration Plans for Pacific Ridge's White Gold Projects
Vancouver, British Columbia--(Newsfile Corp. - June 11, 2026) - Pacific Ridge Exploration Ltd. (TSXV: PEX) (OTCQB: PEXZF) (FSE: PQW) ("Pacific Ridge" or the "Company") is pleased to report that Labrad...
Standard BioTools, Treeline Biosciences to combine in all-stock transaction
Standard BioTools (LAB) and Treeline Biosciences announced they have entered into a definitive merger agreement to combine in an all-stock transaction. Upon completion of the transaction, which is exp...
Standard BioTools and Treeline Biosciences Announce Merger Agreement
Combined company to operate as Treeline Biosciences, advancing a deep pipeline of small molecule inhibitors, protein degraders and targeted therapy antibody-drug conjugates
Standard BioTools Transcript: M&A announcement
The merger creates a well-capitalized precision medicine company with a diverse clinical pipeline and experienced leadership. The all-stock deal, expected to close in 2H 2026, positions the combined entity for accelerated value creation and long-term growth.
Standard BioTools Press release: M&A announcement
Standard BioTools issued a press release on June 8, 2026, disclosing material business information to investors.
Standard BioTools Slides: M&A announcement
Standard BioTools has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Standard BioTools Reports First Quarter 2026 Financial Results
BOSTON, Mass., May 05, 2026 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the quarter ended March 31, 2026.
Standard BioTools Earnings release: Q1 2026
Standard BioTools released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Standard BioTools Quarterly report: Q1 2026
Standard BioTools has published its Q1 2026 quarterly earnings report on May 5, 2026.
Standard BioTools Proxy statement: Proxy filing
Standard BioTools filed a proxy statement on April 27, 2026, providing details for shareholder voting and corporate governance matters.